Suppr超能文献

慢性阻塞性肺疾病加重住院期间发生类固醇诱导性高血糖症的患者发生 2 型糖尿病的风险。

Risk of Future Type 2 Diabetes Mellitus in Patients Developing Steroid-Induced Hyperglycemia During Hospitalization for Chronic Obstructive Pulmonary Disease Exacerbation.

机构信息

Division of Endocrinology, Dimock Community Health Center, Beth Israel Deaconess Medical Center, 55 Dimock Street, Roxbury, Boston, MA, USA.

Division of Endocrinology and Metabolic Medicine, Saint Vincent Hospital, Worcester, MA, USA.

出版信息

Lung. 2020 Jun;198(3):525-533. doi: 10.1007/s00408-020-00356-z. Epub 2020 Apr 28.

Abstract

OBJECTIVE

We evaluated the future risk of developing impaired glucose tolerance and type 2 diabetes mellitus (T2DM) in patient without T2DM who develop hyperglycemia with short-term systemic glucocorticoid therapy during hospitalization.

METHODS

Retrospective analysis was performed on charts of non-diabetic patients admitted with COPD exacerbation and treated with a course of high dose systemic corticosteroid during hospitalization. Patients with BMI over 40 kg/m, endocrinopathy and on medications that could impair glucose tolerance were excluded. Patient data were collected for 1 year after initial hospitalization. Diagnosis of T2DM or IGT was based on the ADA criteria. 311 charts were reviewed, of which 64 patients met our inclusion criteria. Depending on the blood glucose readings during hospitalization, the patients were categorized into two groups: hyperglycemic (> 140 mg/dL; n = 42) and normoglycemic (≤ 140 mg/dL; n = 22).

RESULTS

In the hyperglycemic group, 17/42 (40%) patients developed prediabetes and 5/42 (12%) developed T2DM on follow-up. Interestingly, none of the patients developed IGT or T2DM in the normoglycemic group. Both the groups were well matched in terms of family history of DM, history of hypertension, hyperlipidemia, BMI > 25 kg/m, weight change, tobacco and alcohol use, corticosteroid therapy duration, and cumulative steroid dose. After adjusting for all these risk factors, on logistic regression analysis, hyperglycemic patients had 37 times higher chance of developing IGT, compared to normoglycemic patients (p = 0.003).

CONCLUSIONS

Our study suggests that patients without T2DM with acute exacerbation of COPD who develop steroid-induced hyperglycemia in response to systemic corticosteroid treatment have an increased risk for developing future IGT or T2DM. Bigger studies are needed to support our findings since results drawn from our study have the limitations of smaller sample size (wider confidence interval) in a single center.

摘要

目的

我们评估了在因 COPD 加重而住院并接受短期全身糖皮质激素治疗期间发生高血糖的无 2 型糖尿病(T2DM)患者中,发展为糖耐量受损和 T2DM 的未来风险。

方法

对因 COPD 加重而住院并接受高剂量全身皮质类固醇治疗的非糖尿病患者的病历进行回顾性分析。排除 BMI 超过 40kg/m2、内分泌疾病和服用可能影响葡萄糖耐量的药物的患者。患者数据在初次住院后随访 1 年。T2DM 或 IGT 的诊断基于 ADA 标准。共回顾了 311 份病历,其中 64 名患者符合我们的纳入标准。根据住院期间的血糖读数,将患者分为两组:高血糖组(>140mg/dL;n=42)和正常血糖组(≤140mg/dL;n=22)。

结果

在高血糖组中,42 名患者中有 17 名(40%)发展为糖尿病前期,5 名(12%)发展为 T2DM。有趣的是,正常血糖组中没有患者发展为 IGT 或 T2DM。两组在糖尿病家族史、高血压病史、高血脂、BMI>25kg/m2、体重变化、吸烟和饮酒、皮质类固醇治疗时间和累积类固醇剂量等方面均匹配良好。在校正所有这些危险因素后,在逻辑回归分析中,高血糖患者发生 IGT 的几率是正常血糖患者的 37 倍(p=0.003)。

结论

我们的研究表明,因 COPD 急性加重而接受全身皮质类固醇治疗后发生类固醇诱导性高血糖的无 T2DM 患者,未来发生 IGT 或 T2DM 的风险增加。由于我们的研究结果来自单个中心的小样本量(置信区间较宽),因此需要更大的研究来支持我们的发现。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验